Early Minimally Invasive Removal of Intracerebral Hemorrhage (ENRICH) is a multicenter, randomized and adaptive clinical trial comparing standard medical management to early (<24 hours) surgical hematoma evacuation using minimally invasive parafascicular surgery (MIPS) in the treatment of acute spontaneous supratentorial intracerebral hemorrhage.
MIPS is a safe method that offers the ability to completely remove subcortical lesions and minimize injury to adjacent neural tissue.
The purpose of the ENRICH clinical study is to provide substantial clinical evidence of functional improvement, safety and economic benefit when comparing intracerebral hemorrhage (ICH) evacuation surgery to medical treatment. The principal investigator for the clinical study is Ananth K. Vellimana, MD.
Time is critical for this study, and we need to identify possible candidates as quickly as possible. Criteria for potential candidates:
- Acute, spontaneous lobar ICH
- ICH volume 30-80 mL by the ABC/2 method
- GCS 5-14
If you encounter a patient meeting the inclusion criteria listed above, please contact the study coordinator, John Evans, RN, at (314) 393-8090 as soon as possible for the opportunity to take part in the ENRICH clinical study.